Cannabidiol/hydroxychloroquine

N/A

Report date: 2026/03/28 20:00:32

Base Information

Drug NameCannabidiol/hydroxychloroquine
Drug Alias NameIHL-675AIHL-675
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionAutophagy inhibitorsPhospholipases A2 inhibitorsTransient receptor potential cation channel subfamily V modulators +[8] 
TargetsCannabinoid CB1 receptorCytokinesTransient receptor potential cation channel subfamily V +[5] 
Therapy Area/IndicationsRespiratory Distress Syndrome, AdultArthritis, Rheumatoid
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia
CombinationsYes CannabidiolHydroxychloroquine sulfate
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesIncannex Healthcare Ltd
China Registration ClassN/A

Develop Information

Active CompaniesIncannex Healthcare Ltd
Inactive CompaniesN/A
Active IndicationsRespiratory Distress Syndrome, Adult
Inactive IndicationsArthritis, Rheumatoid

Other Information

ATC CodeN/A
Related LinksN/A